



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

*Available for Immediate Delivery !*

## **THREE ALTERNATIVE SCENARIOS of The Future In Vitro Diagnostics Market**

DESIGNED TO HELP INDUSTRY EXECUTIVES DEVELOP EFFECTIVE CONTINGENCY PLANS THAT BEST ACCOMMODATE UNCERTAINTIES AHEAD.

Scenario I: Business-As-Usual

Scenario II: Economic Austerity

Scenario III: Technological Breakthroughs



VENTURE PLANNING GROUP

[WWW.VPGCORP.COM](http://WWW.VPGCORP.COM)

INFORMATION • INTELLIGENCE • ANALYSIS • INSIGHT

# Table of Contents

## I. INTRODUCTION

## II. EXECUTIVE SUMMARY

A. BUSINESS-AS-USUAL SCENARIO

B. ECONOMIC AUSTERITY SCENARIO

C. TECHNOLOGICAL BREAKTHROUGHS SCENARIO

## III. CONCLUSIONS AND RECOMMENDATIONS

## IV. THE SCENARIOS

A. BUSINESS-AS-USUAL SCENARIO

1. Business Environment

a. Health Care Expenditures

b. Cost-Consciousness

c. Reimbursement

d. Industry Consolidation

e. Managed Care

• PPOs

• HMOs

f. Hospitals

g. Admissions

h. Length of Stay

i. Industry Diversification

j. Physician Demographics

k. Aging Population

• Chronic Illnesses

• Disease Incidence

• Susceptibility to Iatrogenesis

• Multiple Illness Cases

l. Laboratory Regulations

m. The FDA Reform

2. Outlook for the In Vitro Diagnostics Market

a. Government Regulations

b. Centralized Testing

• Hospitals

• Commercial Laboratories

• Blood Banks

• Public Health Laboratories

c. Decentralized Testing

• Personal Testing

• Physician Offices/Group Practices

• Ancillary Hospital Locations

- ERs

- ORs

- ICUs/CCUs

• Cancer Clinics

• Ambulatory Care Centers

• Surgery Centers

• Nursing Homes

• Birth Centers

3. Strategic Implications

a. Testing Patterns

• Test Utilization

• Pre-Admission Testing

• Inpatient Testing

• Outpatient Testing

4. Market Segments

a. Chemistry and Immunoassay

• Introduction

• Future Situation

b. Microbiology and Serology

• Introduction

• Future Situation

c. Hematology and Flow Cytometry

• Introduction

• Future Situation

d. Histology and Cytology

• Introduction

• Future Situation

e. Coagulation

• Introduction

• Future Situation

f. Urinalysis

• Introduction

• Future Situation

g. Blood Banking

• Introduction

• Future Situation

5. Technologies

a. Genomics

• Introduction

• Future Situation

b. Proteomics

• Introduction

• Future Situation

c. DNA Probes

• Introduction

• Future Situation

d. Biochips/Microarrays

• Introduction

• Future Situation

e. Monoclonal Antibodies

• Introduction

• Future Situation

f. Solid Phase Chemistry

• Introduction

• Future Situation

g. Biosensors

• Introduction

• Future Situation

h. Automation and Robotics

• Introduction

• Future Situation

i. Computer-Aided Diagnosis

• Introduction

• Future Situation

6. The New Marketplace

a. Purchasing Influences

b. Marketing Strategies

c. Joint Ventures, Mergers and Licensing

d. Import-Export

e. Potential Market Entrants

f. Who May Not Survive?

## B. ECONOMIC AUSTERITY SCENARIO

1. Business Environment

a. Socio-Political Climate

• Cost-Consciousness

• Government Actions

• Three-Tier System

• Health Rationing

• Voucher System

• Health IRA

b. Hospital Closures

c. Hospital Utilization

d. Hospital Reorganization

e. Physician Regulations

f. Wellness Programs

g. Corporate Responses

h. Academic Research

2. Outlook for the In Vitro Diagnostics Market

a. Test Utilization

• Ordering Practices

• Documentation

• Recertification

b. Technology Regulations

c. New Laboratory Ventures

d. Computers

e. Industrial Medicine

f. Insurance Companies

g. Test Volume and Market Size

3. Strategic Implications

a. Testing Patterns

• Pre-Admission Testing

• Inpatient Testing

• Outpatient Testing

b. Market Segments

• Chemistry and Immunoassay

• Microbiology and Serology

• Hematology and Flow Cytometry

• Histology and Cytology

• Coagulation

• Urinalysis

• Blood Banking

c. Technologies

• Genomics

• Proteomics

• DNA Probes

• Biochips/Microarrays

• Monoclonal Antibodies and Immunoassays

• Automation and Robotics

• Solid Phase Chemistry

• Biosensors

• Computer-Aided Diagnosis

d. The New Marketplace

• Purchasing Influences

• Marketing Strategies

• Joint Ventures, Mergers and Licensing

• Import-Export

• Potential Market Entrants

• Who May Not Survive?

## C. TECHNOLOGICAL BREAKTHROUGHS SCENARIO

1. Business Environment

a. Political/Regulatory Climate

b. R & D Funding

c. Industry-Government Relationship

d. Industry-University Ventures

e. Technological Environment

f. Testing Decentralization

g. Health Care Expenditures

h. Physician Population

i. Hospital Indicators

2. Outlook for the In Vitro Diagnostics Market

a. Overview

b. Genomics

c. Proteomics

d. DNA and RNA Probes

e. Biochips/Microarrays

f. Monoclonal Antibodies

g. Immunoassays

h. Information Technology

i. Laboratory Automation and Robotics

j. Solid Phase Chemistry

k. Biosensors

l. Holography

m. Pharmaceuticals

3. Strategic Implications

a. Testing Patterns

• Pre-Admission Testing

• Inpatient Testing

• Outpatient Testing

• Test Volume and Market Size

b. Market Segments

• Chemistry and Immunoassay

• Microbiology and Serology

• Hematology and Flow Cytometry

• Histology and Cytology

• Coagulation

• Urinalysis

• Blood Banking

c. The New Marketplace

• Purchasing Influences

• Marketing Strategies

• Joint Ventures, Mergers and Licensing

• Import-Export

• Potential Market Entrants

• Who May Not Survive?

## V. APPENDICES: METHODOLOGY

A. The Delphi

B. Cross-Impact Analysis

C. Substitution Modeling

# List of Tables

**Executive Summary Table I:** Business-As-Usual Scenario, Growth Areas in Clinical Laboratory Testing

**Executive Summary Table II:** Economic Austerity Scenario, Growth Areas in Clinical Laboratory Testing

**Executive Summary Table III:** Technological Breakthroughs Scenario, Growth Areas in Clinical Laboratory Testing

**Executive Summary Table IV:** Market Size by Location

**Executive Summary Table V:** Market Size by Laboratory Discipline

**Table-1:** Business-As-Usual Scenario, Health Care Costs by Expenditure Type

**Table-2:** Business-As-Usual Scenario, HMO and PPO Enrollment

**Table-3:** Business-As-Usual Scenario, Selected Hospital Statistics

**Table-4:** Business-As-Usual Scenario, Total Population and Physician Demographics

**Table-5:** Business-As-Usual Scenario, Test Volume by Location

**Table-6:** Business-As-Usual Scenario, Test Distribution by Location

**Table-7:** Business-As-Usual Scenario, Market Size by Location

**Table-8:** Business-As-Usual Scenario, Typical Pre-Admission Tests

**Table-9:** Business-As-Usual Scenario, Test Volume by Laboratory Discipline

**Table-10:** Business-As-Usual Scenario, Market Size By Laboratory Discipline

**Table-11:** Economic Austerity Scenario, Selected Hospital Statistics

**Table-12:** Economic Austerity Scenario, HMO and PPO Enrollment

**Table-13:** Economic Austerity Scenario, Total Population and Physician Demographics

**Table-14:** Economic Austerity Scenario, Major Categories of Overutilized Tests

**Table-15:** Economic Austerity Scenario, Test Volume by Location

**Table-16:** Economic Austerity Scenario, Test Distribution by Location

**Table-17:** Economic Austerity Scenario, Market Size by Location

**Table-18:** Economic Austerity Scenario, Timing Requirements for Selected Laboratory Tests

**Table-19:** Economic Austerity Scenario, Test Volume by Laboratory Discipline

**Table-20:** Economic Austerity Scenario, Market Size by Laboratory Discipline

**Table-21:** Technological Breakthroughs Scenario, HMO and PPO Enrollment

**Table-22:** Technological Breakthroughs Scenario, Total Population and Physician Demographics

**Table-23:** Technological Breakthroughs Scenario, Selected Hospital Statistics

**Table-24:** Technological Breakthroughs Scenario, Test Volume by Location

**Table-25:** Technological Breakthroughs Scenario, Test Distribution by Location

**Table-26:** Technological Breakthroughs Scenario, Market Size by Location

**Table-27:** Technological Breakthroughs Scenario, Test Volume by Laboratory Discipline

**Table-28:** Technological Breakthroughs Scenario, Market Size by Laboratory Discipline